Orphazyme A Revenue Growth Rates (ORPH), Current and Historic Growth - CSIMarket
CSIMarket
 


Orphazyme A  (ORPH)
 

ORPH's Revenue Growth by Quarter and Year

Orphazyme A's Revenue results by quarter and year




ORPH Revenue (in millions $) FY 2021 FY 2020 FY 2019 FY 2018
4th Quarter December 5.76
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 5.76





ORPH Revenue fourth quarter 2021 Y/Y Growth Comment
Orphazyme A in the fourth quarter 2021 achieved Revenue of $ 5.76 millions compare to recorded in same quarter a year ago.

According to the results reported in the fourth quarter 2021, Orphazyme A achieved the best Revenue growth in Major Pharmaceutical Preparations industry. While Orphazyme A' s Revenue no change of 0% ranks overall at the positon no. in the fourth quarter 2021.




ORPH Revenue ( Y/Y Growth %) 2021
2020 2019 2018
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   - - - -

Financial Statements
Orphazyme A's fourth quarter 2021 Revenue $ 5.76 millions ORPH's Income Statement
Orphazyme A's fourth quarter 2020 Revenue $ 0.00 millions Quarterly ORPH's Income Statement


ORPH Revenue (Quarter on Quarter Growth %)

2021
2020 2019 2018
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   - - - -




Revenue fourth quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Revenue fourth quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Revenue by Quarter for the Fiscal Years 2018, 2019, 2020, 2021

Orphazyme A's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ORPH's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ORPH's IV. Quarter Q/Q Revenue Comment


Orphazyme A's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2021)
12 Months Ending
12 Months Ending
12 Months Ending
12 Months Ending
Cumulative Revenue 12 Months Ending $ 36.19 $ 0.00 $ 0.00 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) - - - - -
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) - - - - -
Seq. Revenue Growth (TTM) Overall Ranking # # # # #


Cumulative Revenue growth Comment


Orphazyme A achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Revenue growth Comment


Orphazyme A achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 






Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ORPH's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue no change for the quarter ending Dec 31 2021 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2021
Regenerx Biopharmaceuticals inc -0.01%$ -0.005 millions
Xtant Medical Holdings Inc -0.32%$ -0.321 millions
Biomarin Pharmaceutical Inc-0.51%$ -0.510 millions
Organon and Co -0.62%$ -0.620 millions
Healthcare Services Group Inc -0.65%$ -0.645 millions
Bausch Health Companies Inc -0.77%$ -0.768 millions
Tenet Healthcare Corp-1.20%$ -1.200 millions
Rockwell Medical inc -1.20%$ -1.203 millions
China Pharma Holdings Inc-1.42%$ -1.424 millions
Mimedx Group Inc -1.66%$ -1.662 millions
Adm Tronics Unlimited Inc -1.70%$ -1.703 millions
Marinus Pharmaceuticals Inc -1.75%$ -1.745 millions
Reshape Lifesciences Inc-2.00%$ -1.996 millions
Bicycle Therapeutics Plc-2.00%$ -2.001 millions
Zimmer Biomet Holdings Inc -2.27%$ -2.273 millions
Elanco Animal Health Incorporated-2.34%$ -2.343 millions
Gilead Sciences Inc -2.39%$ -2.385 millions
Axogen inc -2.95%$ -2.948 millions
Acorda Therapeutics Inc -3.12%$ -3.124 millions
Veru Inc -3.30%$ -3.297 millions
Neuronetics Inc -3.58%$ -3.575 millions
Biogen Inc -4.16%$ -4.165 millions
Inmed Pharmaceuticals Inc-4.23%$ -4.230 millions
Pharming Group N v -4.38%$ -4.378 millions
Notable Labs Ltd -4.39%$ -4.390 millions
Semler Scientific inc -4.40%$ -4.398 millions
Cv Sciences Inc -4.42%$ -4.424 millions
Meridian Bioscience Inc -4.92%$ -4.925 millions
Aclaris Therapeutics Inc -5.00%$ -5.000 millions
Sight Sciences Inc -5.18%$ -5.179 millions


About Orphazyme A Revenue Growth Rates (ORPH), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Orphazyme A s (CIK 1764791).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001564590-22-024528
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Orphazyme A s’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.